Azithromycin for RSV-induced Respiratory Failure in Children
A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children
This project looks at whether azithromycin can help children with severe breathing problems caused by RSV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11145744 on NIH RePORTER |
What this research studies
RSV can cause serious lung issues for infants and children, and we currently have limited ways to help them. This project explores if a common antibiotic, azithromycin, can reduce the severity of RSV-induced breathing failure. Researchers believe azithromycin might work by affecting a specific protein in the body called MMP-9, which plays a role in RSV disease. This large-scale effort will involve many hospitals working together to understand if azithromycin can make a real difference for these children.
Who could benefit from this research
Good fit: Ideal candidates are infants and children aged 0-11 years who are experiencing acute respiratory failure due to RSV infection and require mechanical ventilation.
Not a fit: Patients who do not have RSV-induced respiratory failure or are outside the specified age range may not receive direct benefit from this particular intervention.
Why it matters
Potential benefit: If successful, this could provide a new and effective treatment to reduce hospital stays and improve outcomes for children suffering from severe RSV infection.
How similar studies have performed: A previous Phase II trial showed that azithromycin was safe and linked to shorter hospital stays and lower levels of a specific inflammatory marker in mechanically-ventilated children.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Kong, Michele — University of Alabama at Birmingham
- Study coordinator: Kong, Michele
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.